SVRA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.117

-10.25%

-0.120

-0%

-0.122

-12.5%

Estimates Revision

The market is revising No Change the revenue expectations for Savara Inc. (SVRA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 77.13%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.13%

In Past 3 Month

Stock Price

Go Up

+77.13%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast SVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SVRA is 10.43 USD with a low forecast of 7.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 6.430

Low

7.00

Averages

10.43

High

16.00

Current: 6.430

Low

7.00

Averages

10.43

High

16.00

Oppenheimer

Outperform

maintain

$8 -> $9

2025-11-14

Reason

Oppenheimer

Price Target

$8 -> $9

2025-11-14

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Savara to $9 from $8 and keeps an Outperform rating on the shares. Ahead of December 2025 BLA submission for MOLBREEVI, the firm continues to see a more than $1B opportunity for MOLBREEVI in aPAP following recent updated claims data giving line of sight to at least 1,000 patients by launch with 750 already identified.

Citizens JMP

Jonathan Wolleben

Outperform

downgrade

$11 -> $10

2025-11-13

Reason

Citizens JMP

Jonathan Wolleben

Price Target

$11 -> $10

2025-11-13

downgrade

Outperform

Reason

Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on Savara to $10 from $11 and keeps an Outperform rating on the shares. Savara remains on track to resubmit its biologics license application for Molbreevi in December, with an MAA submission in the EU and UK expected in 1Q26, the analyst tells investors in a research note. The firm is impressed with management's execution on quickly resolving manufacturing deficiencies that prompted a complete response letter in May.

Citizens JMP

Outperform

maintain

$8 -> $11

2025-10-23

Reason

Citizens JMP

Price Target

$8 -> $11

2025-10-23

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Savara to $11 from $8 and keeps an Outperform rating on the shares. The firm's pulmonologist survey indicates high demand for Molbreevi. 60% of those surveyed want to use Molbreevi, which should translate to blockbuster sales, the analyst tells investors in a research note. Citizens says Savara remains on track to resubmit its application for Molbreevi in December.

LifeSci Capital

Francois Brisebois

Outperform

initiated

$11

2025-10-14

Reason

LifeSci Capital

Francois Brisebois

Price Target

$11

2025-10-14

initiated

Outperform

Reason

LifeSci Capital analyst Francois Brisebois initiated coverage of Savara with an Outperform rating and $11 price target.

Guggenheim

Buy

maintain

$8 -> $11

2025-09-09

Reason

Guggenheim

Price Target

$8 -> $11

2025-09-09

maintain

Buy

Reason

Guggenheim raised the firm's price target on Savara to $11 from $8 and keeps a Buy rating on the shares following what the firm calls "a series of positive updates from the company" over the past several weeks. Following these updates, the firm now estimates peak probability-adjusted annual U.S. Molbreevi sales of $962M, up from a prior view of $680M, the analyst tells investors.

Oppenheimer

Outperform

maintain

$6 -> $8

2025-09-08

Reason

Oppenheimer

Price Target

$6 -> $8

2025-09-08

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Savara to $8 from $6 and keeps an Outperform rating on the shares following updated analysis pointing to 5,500 aPAP patients in the U.S. from previous estimates of 3,600 in 2023. This refreshed analysis of claims data giveline of sight to at least 1,000 patients by launch with 750 patients already identified. With no approved therapies in the U.S. to treat aPAP, these claims data reinforce the unmet need ahead of MOLBREEVI BLA submission in December, the firm says. With the analytical package being finalized and the recent NEJM publication underscoring the MOLBREEVI's ability to address the underlying pathophysiology of aPAP, Oppenheimer is increasingly confident in a potential August 2026 approval, if granted Priority Review.

Valuation Metrics

The current forward P/E ratio for Savara Inc (SVRA.O) is -15.69, compared to its 5-year average forward P/E of -7.00. For a more detailed relative valuation and DCF analysis to assess Savara Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.00

Current PE

-15.69

Overvalued PE

-4.04

Undervalued PE

-9.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.38

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.12

Undervalued EV/EBITDA

-4.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

17.84

Current PS

0.00

Overvalued PS

105.18

Undervalued PS

-69.50

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 373.33% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 373.33% over the last month.

Sold

Bought

SVRA News & Events

Events Timeline

No data

News

3.5

12-11Newsfilter

Savara Secures European Patent for MOLBREEVI Until March 2041

9.0

12-02Yahoo Finance

Savara and PARI Awarded European Patent for Drug-Device Combination

8.5

12-02SeekingAlpha

Savara Inc. Rises in Value Amid Acquisition Rumors

People Also Watch

Frequently Asked Questions

What is Savara Inc (SVRA) stock price today?

The current price of SVRA is 6.43 USD — it has decreased -2.72 % in the last trading day.

What is Savara Inc (SVRA)'s business?

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

What is the price predicton of SVRA Stock?

What is Savara Inc (SVRA)'s revenue for the last quarter?

Savara Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Savara Inc (SVRA)'s earnings per share (EPS) for the last quarter?

Savara Inc. EPS for the last quarter amounts to -0.14 USD, increased 27.27 % YoY.

What changes have occurred in the market's expectations for Savara Inc (SVRA)'s fundamentals?

How many employees does Savara Inc (SVRA). have?

Savara Inc (SVRA) has 59 emplpoyees as of December 16 2025.

What is Savara Inc (SVRA) market cap?

Today SVRA has the market capitalization of 1.34B USD.